Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.42 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29659087 | 1.00 | CYP17A1 (0.52) | CYP17A1MAP2K1KCNQ4KCNQ5MAP2K2 | |
| SCHEMBL18522602 | 0.86 | HPGD (0.46) | CYP17A1KCNQ4KCNQ5RXFP1 | |
| SCHEMBL16590417 | 0.85 | GAA (0.43) | CYP17A1MAP2K1MAP2K2NPC1GAA | |
| SCHEMBL5868826 | 0.85 | AAK1 (0.46) | CYP17A1RXFP1GAA | |
| SCHEMBL857284 | 0.84 | HTT (0.55) | CYP17A1KCNQ4KCNQ5NPC1GAA | |
| SCHEMBL15925258 | 0.84 | CYP17A1 (0.54) | CYP17A1KCNQ4KCNQ5RXFP1SMN1; SMN2 | |
| SCHEMBL15058173 | 0.84 | HPGD (0.51) | MAP2K1MAP2K2NPC1GAARAB9A | |
| SCHEMBL2363945 | 0.83 | CYP17A1 (0.53) | CYP17A1KCNQ4KCNQ5RXFP1HTT | |
| SCHEMBL557858 | 0.83 | SMN1; SMN2 (0.46) | CYP17A1KCNQ4KCNQ5RXFP1SMN1; SMN2 | |
| SCHEMBL12715634 | 0.83 | KCNQ4 (0.40) | CYP17A1KCNQ4KCNQ5RXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102026996-B | Pyridazine derivatives as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2015-01-07 | — | — | CN | disclosed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| CN-102448938-A | Dihydropyridine sulfonamides and dihydropyridine sulfamides as MEK inhibitors | ARDEA BIOSCIENCES INC | 2012-05-09 | — | — | CN | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| CN-102026996-A | Pyridazine derivatives as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-20 | — | — | CN | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | CYP17A1 1025/4885MAP2K1 185/4885KCNQ4 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.